MX2016007748A - Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders. - Google Patents
Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders.Info
- Publication number
- MX2016007748A MX2016007748A MX2016007748A MX2016007748A MX2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- benzylpropionamide
- dioxol
- benzo
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title 1
- SRADCMOCDMFMPS-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-n-benzylpropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CC)CCC(C=1C=C2OCOC2=CC=1)C1=CC=CC=C1OC SRADCMOCDMFMPS-UHFFFAOYSA-N 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000006439 vascular pathology Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides methods for impairing function or reducing or ablating levels of Id (inhibitors of differentiation) proteins to suppress metastasis of cancer cells in mammalian subjects presenting with cancer or elevated risk of metastatic disease. Exemplary anti-Id compounds include N-(3-(benzo[d] [1,3]dioxol-5-yl)-3-(2-methoxyphenyl)propyl)-N- benzylpropionamide and isolated enantiomers of N-(3-(benzo[d] [ 1,3]dioxol-5-yl)-3-(2- methoxyphenyl)propyl)-N-benzylpropionamide. Anti-Id compositions and methods of the invention can be combined with standard anticancer treatment modalities, such as surgery, radiation and chemotherapy. Also provided are compositions and methods to treat other hyperproliferative disorders, including pathogenic angiogenic conditions, including tumor-associated neoangiogenesis and ocular vascular pathologies including age-related macular degeneration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916116P | 2013-12-13 | 2013-12-13 | |
| US201461965776P | 2014-02-06 | 2014-02-06 | |
| PCT/US2014/070221 WO2015089495A2 (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007748A true MX2016007748A (en) | 2017-07-28 |
Family
ID=53371974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007748A MX2016007748A (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3079680A4 (en) |
| JP (2) | JP2017506257A (en) |
| CN (1) | CN107847470A (en) |
| AU (1) | AU2014361814A1 (en) |
| MX (1) | MX2016007748A (en) |
| WO (1) | WO2015089495A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11000548B2 (en) * | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| KR20180110141A (en) | 2016-02-18 | 2018-10-08 | 엔리벡스 테라퓨틱스 리미티드 | Combination of immunotherapy and cytokine regulating therapy to treat cancer |
| LU100900B1 (en) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | COMPOUNDS FOR MODULATING A-KETOGLUTARIC ACID (2KG) -DEPENDENT OXYGENASES |
| EP3760614B8 (en) * | 2019-07-02 | 2022-04-27 | Universität Heidelberg | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |
| US20220356163A1 (en) * | 2019-10-01 | 2022-11-10 | Memorial Sloan Kettering Cancer Center | SMALL MOLECULE INHIBITORS OF Id PROTEINS |
| CN113627763B (en) * | 2021-07-30 | 2023-12-01 | 厦门大学 | A method for establishing a quantitative risk assessment model |
| CN114480490A (en) * | 2021-12-31 | 2022-05-13 | 四川省医学科学院·四川省人民医院 | Method for constructing animal model of retinal neovascular diseases |
| CN115487358B (en) * | 2022-08-05 | 2023-05-30 | 核工业四一六医院 | Gel composite scaffold for cartilage tissue repair and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| WO2012000036A1 (en) * | 2010-06-30 | 2012-01-05 | Garvan Institute Of Medical Research | Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1 |
| WO2013025939A2 (en) * | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
-
2014
- 2014-12-14 WO PCT/US2014/070221 patent/WO2015089495A2/en not_active Ceased
- 2014-12-14 JP JP2016558543A patent/JP2017506257A/en active Pending
- 2014-12-14 MX MX2016007748A patent/MX2016007748A/en unknown
- 2014-12-14 CN CN201480075495.2A patent/CN107847470A/en active Pending
- 2014-12-14 AU AU2014361814A patent/AU2014361814A1/en not_active Abandoned
- 2014-12-14 EP EP14870415.8A patent/EP3079680A4/en not_active Withdrawn
-
2019
- 2019-09-06 JP JP2019162598A patent/JP2019203028A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107847470A (en) | 2018-03-27 |
| WO2015089495A3 (en) | 2015-11-12 |
| AU2014361814A1 (en) | 2016-07-28 |
| EP3079680A4 (en) | 2017-11-22 |
| JP2017506257A (en) | 2017-03-02 |
| WO2015089495A2 (en) | 2015-06-18 |
| EP3079680A2 (en) | 2016-10-19 |
| JP2019203028A (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007748A (en) | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| CL2012003604A1 (en) | Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others. | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| EA201391416A1 (en) | NEW CONNECTIONS AS PROTEINKINASE MODULATORS | |
| MX2017016134A (en) | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease. | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| EA201790267A1 (en) | NEW KINAZ MODULATORS | |
| PH12015501370B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| UA116774C2 (en) | Serine/threonine kinase inhibitors | |
| EA201291098A1 (en) | NEW CONNECTIONS OF 3,5-DESIGNED-3H-IMIDAZO [4,5-B] Pyridine and 3,5-DESIGNED -3H- [1,2,3] TRIAZOLO [4,5-B] Pyridine as modulators of protein kinase | |
| CL2012000592A1 (en) | Compounds derived from phenoxy or phenyl-thieno [3,2-b] pyridine, tyrosine kinase inhibitors; pharmaceutical composition; and its use in the treatment of colorectal, lung, hematological, liver, breast cancer, in diabetic retinopathy, macular degeneration, glaucoma, psoriasis, diabetes, neurodegenerative diseases, among others. | |
| MX357502B (en) | Pyrrolotriazinone derivatives. | |
| MY172308A (en) | Bicyclic pyrazinone derivatives | |
| EA201491520A1 (en) | NEW CONNECTIONS OF 3,5-DESIGNED-3H-IMIDAZO [4,5-b] Pyridine and 3,5-DESIGNED-3H- [1,2,3] TRIAZOLO [4,5-b] Pyridine as modulators of C-met PROTEINKINASE | |
| MX362939B (en) | (aza-)isoquinolinone derivatives. | |
| MX2012006822A (en) | 1, 7 - diazacarbazoles and their use in the treatment of cancer. | |
| EA201792103A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES | |
| MX2016014436A (en) | Heterocyclyl-butanamide derivatives. | |
| MX377304B (en) | PIPERAZINE DERIVATIVES AS MODULATORS OF LIVER X RECEPTORS. | |
| MX357888B (en) | Base addition salts of nitroxoline and uses thereof. | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| MX2016004212A (en) | A tor kinase inhibitor in the prevention or treatment of cancer characterized by gene mutations. |